SIB-Norwegian Version, Validation and Reliability Study

The purpose of this study is to validate and to test interrater reliability for the Norwgian version of Severe Impairment Battery (SIB).

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Dementia Brain Diseases Central Nervous System Diseases Diagnostic Tests, Routine Mental Disorders Nervous System Diseases Neurocognitive Disorders

Sex eligibility

All sexes

Study type

Observational

Primary location

Sykehuset Innlandet HF - Sanderud

Ottestad, Oppland, 2312, Norway

About this study

The study will include 60 persons with mild to severe dementia. To test the validation of SIB, we will interview the included persons with Severe Impairment Battery (SIB) and compare the results with Clinical Dementia Rating (CDV)reported by their nurses. To test interrater reliability 30 of the included persons will be interviewed with SIB by two different raters, and the two raters results will be compared.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Dementia, mild to severe.
Nursing Home resident

Exclusion criteria

No ability to write or read.
Physical handicapped, unable to use hands.

Treatment and study plan

Diagnostic Screening

Behavioral

Sponsors and collaborators

Lead sponsor

Sykehuset Innlandet HF

Other

Registry information

Official study title

Severe Impairment Study - Norwegian Version. A Validation and Reliability Study.

Important dates

Study start: 2007
Study completion: 2007
First posted: Mar 20, 2007
Registry last updated: Jul 3, 2007

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed